Pharmsynthez Share Price

LIFE

RU000A0JR514

Pharmaceuticals

End-of-day quote Moscow Micex - RTS Other stock markets 08/07/2022			5-day change	1st Jan Change
4.505 ^RUB	+10.15%		-.--%	-

06-02	Public Joint-Stock Company "Pharmsynthez" Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-07	Public Joint-Stock Company "Pharmsynthez" Reports Earnings Results for the Full Year Ended December 31, 2025	CI

Farmsintez PAO (Farmsintez OJSC) is a Russia-based company, which is engaged in the pharmaceutical sector. The Company focuses on the medical research, development and manufacture of drugs ingredients used in oncology, gynecology, tuberculosis therapy and others. In addition, Farmsintez OAO offers chemical research services, chemical technology development and quality control services. The Company sells its products domestically, as well as abroad, including the Commonwealth of Independence State (CIS) countries. It has two wholly owned subsidiaries located in Moscow and Tallin, Estonia. As of May 21, 2011, the Companyâ€™s major shareholder was EphaG AS with a stake of 69.23%. In April 2013, the Company acquired the pharmacies of Guardum Pharmaceuticals in the U.S. state of Florida.

Employees

Sector

Pharmaceuticals

More about the company

Stock Market
Stocks
LIFE Stock

Google lets you customize your preferred sources.

Choose MarketScreener

Market Cap	1.36B 104B 1.19B 1.09B 1.01B 1.92B 129B 1.96B 13.11B 5.1B 63.52B 5.09B 4.98B 220B	P/E 2021	-2.42x	P/E 2022	-6.53x
Enterprise Value	2.09B 160B 1.83B 1.69B 1.56B 2.97B 199B 3.02B 20.23B 7.87B 98B 7.86B 7.68B 339B	EV / Sales 2021	5.43x	EV / Sales 2022	5.51x
Free-Float	95.22%	Yield 2021 *	-	Yield 2022	-

06-02	Public Joint-Stock Company "Pharmsynthez" Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-07	Public Joint-Stock Company "Pharmsynthez" Reports Earnings Results for the Full Year Ended December 31, 2025	CI
11-27	Public Joint-Stock Company "Pharmsynthez" Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
29/08/25	Public Joint-Stock Company "Pharmsynthez" Reports Earnings Results for the Half Year Ended June 30, 2025	CI
27/09/23	Public Joint-Stock Company "Pharmsynthez" Reports Earnings Results for the Half Year Ended June 30, 2023	CI
18/05/23	Public Joint-Stock Company "Pharmsynthez" Auditor Raises 'Going Concern' Doubt	CI
18/05/23	Public Joint-Stock Company "Pharmsynthez" Reports Earnings Results for the Full Year Ended December 31, 2022	CI
07/11/22	Public Joint-Stock Company "Pharmsynthez" announced that it expects to receive funding from Central Bank of the Russian Federation	CI
27/04/22	Public Joint-Stock Company "Pharmsynthez" Auditor Raises 'Going Concern' Doubt	CI
11/11/21	Public Joint-Stock Company "Pharmsynthez" Reports Earnings Results for the Half Year Ended June 30, 2021	CI
15/10/21	Xenetic Biosciences, Inc. Enters into Amendment Number One to Master Services Agreement with PJSC Pharmsynthez	CI
14/04/21	Market Chatter: South Korean Regulator Rejects Thelma Therapeutics's Phase Three Trial for COVID-19 Cure	MT
01/03/21	Public Joint-Stock Company Pharmsynthez Reports Earnings Results for the Full Year Ended December 31, 2018	CI

5 years	2.64		7
10 years	2.64		18.75

Manager	Title	Age	Since
Petr Vladimirovich Kruglyakov CEO	Chief Executive Officer	48	31/12/2013
Alexey Shafranov DFI	Director of Finance/CFO	47	-
Dmitriy Nikolayevich Poznyak CTO	Chief Tech/Sci/R&D Officer	-	-

Director	Title	Age	Since
Dmitriy Genkin CHM	Chairman	57	31/12/2004
Indrek Kasela BRD	Director/Board Member	54	31/12/2006
Steve Gorelik BRD	Director/Board Member	47	31/12/2006

Pharmsynthez Share Price

Stocks

LIFE

RU000A0JR514

Pharmaceuticals

Valuation: Pharmsynthez

Latest news : Pharmsynthez

Quotes and Performance

Course Extremes

Managers and Directors: Pharmsynthez

Other Pharmaceuticals

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PHARMSYNTHEZ	+10.15%	-.--%	-.--%	-.--%	25.27M
ELI LILLY AND COMPANY	+2.96%	+3.01%	+59.87%	+173.31%	1,070B
JOHNSON & JOHNSON	+3.05%	+5.23%	+72.11%	+67.81%	624B
ABBVIE INC.	-0.04%	+1.20%	+35.72%	+87.93%	450B
ROCHE HOLDING AG	-2.58%	-2.07%	+27.62%	+22.57%	328B
NOVARTIS AG	+1.36%	+0.17%	+29.90%	+49.33%	284B
NOVO NORDISK A/S	+1.98%	+4.08%	-25.78%	-39.02%	217B
AMGEN INC.	+0.45%	+1.65%	+25.65%	+68.35%	198B
GILEAD SCIENCES, INC.	+5.21%	+7.93%	+21.99%	+83.23%	161B
PFIZER INC.	+1.48%	-0.04%	-4.64%	-32.25%	135B
Average	+1.79%	+2.99%	+24.24%	+48.13%	346.75B
Weighted average by Cap.	+0.29%	+2.51%	+41.85%	+87.34%

	2021	2022
Net sales	438M 33.58B 384M 354M 328M 622M 41.6B 632M 4.24B 1.65B 20.53B 1.65B 1.61B 70.96B	380M 29.09B 332M 306M 284M 539M 36.03B 547M 3.67B 1.43B 17.78B 1.43B 1.39B 61.47B
Net income	-698M -53.44B -610M -563M -521M -990M -66.2B -1.01B -6.75B -2.62B -32.67B -2.62B -2.56B -113B	-207M -15.9B -182M -167M -155M -294M -19.69B -299M -2.01B -780M -9.72B -779M -762M -33.59B
Net Debt	693M 53.08B 606M 559M 518M 983M 65.76B 999M 6.7B 2.61B 32.46B 2.6B 2.55B 112B	736M 56.4B 644M 594M 550M 1.04B 69.87B 1.06B 7.12B 2.77B 34.48B 2.76B 2.7B 119B